Business Wire

Jam City Launches Harry Potter: Hogwarts Mystery On the App Store and Google Play

Del

Jam City, a Los Angeles based mobile games studio, announced today that the new mobile game Harry Potter: Hogwarts Mystery is available to download now on the App Store and Google Play. Developed by Jam City in partnership with Warner Bros. Interactive Entertainment, Harry Potter: Hogwarts Mystery is the first mobile game where players create their own character and experience life as a Hogwarts student. The game will launch under Warner Bros. Interactive Entertainment's Portkey Games, a label dedicated to creating new mobile and videogame experiences that place the player at the center of their own adventure, inspired by J.K. Rowling’s original stories.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180425005082/en/

Play Harry Potter: Hogwarts Mystery today! www.HarryPotterHogwartsMystery.com/ (Graphic: Business Wi ...

Play Harry Potter: Hogwarts Mystery today! www.HarryPotterHogwartsMystery.com/ (Graphic: Business Wire)

“There are so few moments where a mobile entertainment company has the chance to truly bring magic into the world and we’ve been thrilled by the amazing response our game has already received from Harry Potter fans everywhere,” said Chris DeWolfe, co-founder and CEO of Jam City. “We at Jam City have been working hard to ensure that any aspiring witch or wizard can enter Hogwarts through their smartphones and tablets and begin their magical journeys.”

The story of Harry Potter: Hogwarts Mystery is set in the 1980s. In the game, players will progress as a student through Hogwarts, joining one of its four houses. Players will be able to create and upgrade personalized characters using an avatar customization system, learn an arsenal of magical skills, and form relationships with other students. They will also be able to master everything from crafting potions under Snape’s critical eye, to Transfiguration with Professor McGonagall. Along with interactive spellcasting, the game features an encounter system where narrative choices impact parts of the story.

"Being involved in the making of the Harry Potter: Hogwarts Mystery mobile game will give great pleasure to my grandchildren,” said Dame Maggie Smith, voice of Professor McGonagall in the game.

Players will also be introduced to some original game characters like Penny, a popular Hufflepuff potions expert, Tulip, a rebellious Ravenclaw prankster, and Merula, a Slytherin with a dark past. As players unravel the Hogwarts mystery, they will explore familiar locations like Diagon Alley and Hogsmeade.

Harry Potter: Hogwarts Mystery is free to play and is available NOW on mobile devices via the App Store and Google Play. For more details on Harry Potter: Hogwarts Mystery , and to connect with other Harry Potter fans, visit www.facebook.com/HPHogwartsMystery/, www.twitter.com/HogwartsMystery, and for more information visit www.HarryPotterHogwartsMystery.com/.

About Jam City:

Jam City is a global leader in mobile entertainment, providing social gaming experiences for millions of players around the world. Jam City was founded in 2010 by MySpace cofounders Chris DeWolfe and Aber Whitcomb, and former 20th Century Fox executive Josh Yguado. Jam City is the creative powerhouse behind some of the highest grossing and most enduring social gaming franchises for mobile, including Cookie Jam (Facebook “Game of the Year” winner) and Panda Pop. Jam City is the go-to studio for Hollywood, having developed immersive, narrative rich mobile games around iconic entertainment brands including Harry Potter, Family Guy and Marvel Avengers. Jam City has 500 employees across studios in Los Angeles (HQ), San Francisco, San Diego, Bogota and Buenos Aires. The Jam City team is known for its creative excellence and technological innovation in key areas including storytelling, data science and consumer insights.

About Warner Bros. Interactive Entertainment:

Warner Bros. Interactive Entertainment, a division of Warner Bros. Home Entertainment, Inc., is a premier worldwide publisher, developer, licensor and distributor of entertainment content for the interactive space across all platforms, including console, handheld, mobile and PC-based gaming for both internal and third party game titles.

About Portkey Games:

Portkey Games, from Warner Bros. Interactive Entertainment, is the games label dedicated to creating new Wizarding World mobile and videogame experiences that place the player at the center of their own adventure, inspired by J.K. Rowling’s original stories. Portkey Games offers players the opportunity to make their own narrative choices and engage with the Wizarding World setting to discover new and unique experiences. The label was created to bring gamers and fans new gaming experiences that allow them to delve into the Wizarding World in immersive ways where they can create their own magical story.

About the Harry Potter Series:

Harry Potter continues to be a global phenomenon. Each of the seven books by author J.K. Rowling has broken sales records, with the series to date having sold over 500 million copies worldwide and translated into over 80 languages. The Harry Potter films, produced by Warner Bros. Pictures, have grossed more than $7.7 billion to date worldwide at the box office, making Harry Potter one of the largest-grossing film franchise in history.

HARRY POTTER: HOGWARTS MYSTERY software © 2018 Jam City, Inc. Developed by Jam City. Jam City® and the Jam City Logo are registered and/or unregistered trademarks of Jam City, Inc. WIZARDING WORLD, HARRY POTTER and FANTASTIC BEASTS Publishing Rights © J.K. Rowling. PORTKEY GAMES, HARRY POTTER: HOGWARTS MYSTERY, WIZARDING WORLD, HARRY POTTER and FANTASTIC BEASTS characters, names and related indicia © and ™ Warner Bros. Entertainment Inc. All Rights Reserved.

WB GAMES LOGO, WB SHIELD: ™ & © Warner Bros. Entertainment Inc. (s18)

Editor’s Note:

60 SECOND VIDEO NEWS RELEASE - HIGH RESOLUTION VIDEO

90 SECOND VIDEO NEWS RELEASE - HIGH RESOLUTION VIDEO

B-ROLL PACKAGE - HIGH RESOLUTION VIDEO

Contact information

Media Contacts:
for Jam City
Sarah Ross, 310-924-1404
sarahr@jamcity.com
or
Jam City
Kenny Johnston, 602-999-1890
KJohnston@jamcity.com
or
ONE PR Studio (for Jam City in the US)
Kjell Vistad | Gilberto Williams-Gamboa
510-893-3271
jamcity@oneprstudio.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting20.10.2018 22:30Pressemelding

Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents. The data, which are being presented as a late-breaking poster at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Chicago, suggest filgotinib has a potential role in addressing important unmet needs in the treatment of rheumatoid arthritis. Positive efficacy data from FINCH 2 were previously announced in September 2018. The data show statistically significant improvements in the proportion of patients achieving a range of clinical efficacy endpoints, including the proportion of patients achieving American College of Rheumatology 20 percent (ACR20, primary endpoint), 50 percent

Manchester United and True Religion Launch Denim Range19.10.2018 17:37Pressemelding

Manchester United (NYSE:MANU) and luxury denim brand True Religion have collaborated to launch a range of premium club branded denim wear. A first for the club, the new global partnership with the iconic American denim brand will see a range of men’s & women’s co-branded styles go on sale beginning 26th October in the club’s Megastore as well as online via United Direct and truereligion.com & eu.truereligion.com. The exclusive collection features jeans, shirts and jackets, including a highly desirable limited edition denim jacket embroidered with the club’s crest. Fans will have the opportunity to win a selection of clothing from the new range by visiting www.manutd.com/truereligion. Manchester United’s Group Managing Director, Richard Arnold, comments: “True Religion is a well-known, established name in fashion, creating unique designs without compromising on quality. The range we have collaborated on includes the same attention to detail and craftsmanship that has made True Religion

Arch Insurance Announces Strategic Leadership Changes19.10.2018 13:10Pressemelding

Arch Insurance today announced that Matt Shulman will assume the newly created role of CEO, Arch Insurance North America, effective January 1, 2019. In this role, he will lead Arch Insurance’s operations in the United States and Canada. He will report to Nicolas Papadopoulo, Chairman and CEO of Arch Worldwide Insurance Group. Mr. Shulman, who has more than 20 years of experience in the insurance industry, has been with Arch Insurance since 2009 and has served as the President and CEO of Arch Insurance Europe since 2016. “Matt brings significant U.S. and international experience to this role. Under his leadership, together with our senior team, Arch Insurance will continue to enhance our value proposition to our customers through a robust, diversified product portfolio, creative solutions and excellent service,” Mr. Papadopoulo said. Arch Insurance has also created a new organizational structure with three Chief Underwriting Officers (CUO) dedicated to specific lines of business. These

Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer19.10.2018 12:00Pressemelding

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1 st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients. Data for these secondary endpoints will be presented in a poster discussion at the European Society for Medical Oncology (ESMO) 2018 Congress on Friday, October 19 at 2:00 p.m. CET in Munich, Germany. These results further support ALUNBRIG as a potential treatment for adults with ALK+ locally advanced or metastatic NSCLC who had not received a prior ALK inhibitor. ALUNBRIG is currently not approved as first-line therapy for advanced ALK+ NSCLC. “ALK+ NSCLC often spreads to the brain, so having options that can clearly demonstrate efficacy both in the brain an

Vertex Receives European CHMP Positive Opinion for KALYDECO® (ivacaftor) to Treat Patients With Cystic Fibrosis Aged 12 to <24 months With Certain Mutations in the CFTR Gene19.10.2018 11:54Pressemelding

Vertex Pharmaceuticals (Europe) Limited today announces that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for KALYDECO® (ivacaftor) to include the treatment of people with cystic fibrosis (CF) aged 12 to <24 months who have at least one of the following nine mutations in their cystic fibrosis transmembrane conductance regulator (CFTR) gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. If the European Commission issues a favorable adoption of the EMA CHMP opinion for the extension of indication, ivacaftor will be the first and only medicine approved in Europe to treat the underlying cause of CF in patients aged 12 to <24 months, who have specific mutations in the CFTR gene. “Cystic fibrosis is a chronic, progressive disease that is present at birth, with symptoms often occurring in infancy, so early treatment is crucial to deliver the best possible outcomes for patients,” said Reshma Kewalr

Schlumberger Announces Third-Quarter 2018 Results19.10.2018 11:00Pressemelding

Schlumberger Limited (NYSE: SLB) today reported results for the third quarter of 2018. (Stated in millions, except per share amounts) Three Months Ended Change Sept. 30, 2018 Jun. 30, 2018 Sept. 30, 2017 Sequential Year-on-year Revenue $8,504 $8,303 $7,905 2% 8% Pretax operating income $1,152 $1,094 $1,059 5% 9% Pretax operating margin 13.5% 13.2% 13.4% 36 bps 15 bps Net income - GAAP basis $644 $430 $545 50% 18% Net income, excluding charges & credits* $644 $594 $581 8% 11% Diluted EPS - GAAP basis $0.46 $0.31 $0.39 48% 18% Diluted EPS, excluding charges & credits* $0.46 $0.43 $0.42 7% 10% North America revenue $3,189 $3,139 $2,602 2% 23% International revenue $5,215 $5,065 $5,147 3% 1% North America revenue, excluding Cameron $2,572 $2,546 $2,086 1% 23% International revenue, excluding Cameron $4,559 $4,387 $4,430 4% 3% *These are non-GAAP financial measures. See section below entitled "Charges & Credits" for details. Schlumberger Chairman and CEO Paal Kibsgaard commented, “Our third